A novel BLyS antagonist peptide designed based on the 3-D complex structure of BCMA and BLyS

Biochemical and Biophysical Research Communications

Volumn 346, Issue 4, 2006, Pages 1158-1162

  Sun, Jian ^a,b   Feng, Jiannan ^b   Li, Yan ^b   Shen, Beifen ^b  

^a TIANJIN UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Antagonist; B cell maturation antigen (BCMA); B lymphocyte stimulator (BLyS); Computer guided molecular design; Molecular docking

Indexed keywords

ANTIBODY; ANTIGEN; B CELL MATURATION ANTIGEN; B LYMPHOCYTE STIMULATOR; B LYMPHOCYTE STIMULATOR ANTAGONIST; IMMUNOGLOBULIN FC FRAGMENT; PEPTIDE DERIVATIVE; PEPTIDE PT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; THEORETICAL STUDY;

ANIMALS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; B-CELL MATURATION ANTIGEN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE PROTEINS; MICE; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, TUMOR NECROSIS FACTOR; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745417203     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.005     Document Type: Article

References (19)

1. Moore P.A., Belvedere O., Orr A., Pier K., Ladler D.W., Fang P., Sopped D., Charters M., Gents R., Par melee D., Li Y., Galleria O., Geri J., Roche V., Nardelli B., Carrell J., Sosnovtseva S., Greenfield W., Ruben S.M., Olsen H.S., Fikes J., and Hilbert D.M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 286 (1999) 260-263
2. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., Ambrose C., Lawton P., Bixler S., Acha-Orbea H., Valmori D., Romero P., Werner-Favre C., Zubler R.H., Browning J.L., and Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189 (1999) 1747-1756
3. Shu H.B., Hu W.H., and Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukoc. Biol. 65 (1999) 680-683
4. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., Frew E., and Scott M.L. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293 (2001) 2111-2114
5. Khare S.D., Sarosi I., Xia X.Z., McCabe S., Miner K., Solovyev I., Hawkins N., Kelley M., Chang D., Van G., Ross L., Delaney J., Wang L., Lacey D., Boyle W.J., and Hsu H. Severe B cell hyperplasia and autoimmune diseases in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97 (2000) 3370-3375
6. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., Xu W., Parrish-Novak J., Foster D., Lofton-Day C., Moore M., Littau A., Grossman A., Haugen H., Foley K., Blumberg H., Harrison K., Kindsvogel W., and Clegg C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
7. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., Hession C., Schneider P., Sizing I.D., Mullen C., Strauch K., Zafari M., Benjamin C.D., Tschopp J., Browning J.L., and Ambrose C. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293 (2001) 2108-2111
8. O'Connor B.P., Raman V.S., Erickson L.D., Cook W.J., Weaver L.K., Ahonen C., Lin L.L., Mantchev G.T., Bram R.J., and Noelle R.J. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199 (2004) 91-98
9. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., Tschopp J., Cachero T.G., Batten M., Wheway J., Mauri D., Cavill D., Gordon T.P., Mackay C.R., and Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109 (2002) 59-68
10. Cheema G.S., Roschke V., Hilbert D.M., and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthrit. Rheum. 44 (2001) 1313-1319
11. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., and Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20 (2004) 785-798
12. Doolittle R.F. Stein and Moore award address. Reconstructing history with amino acid sequences. Protein Sci. 1 (1992) 191-200
13. Li B., Tom J.Y.K., Oare D., Yen R., Fairbrother W.J., Wells J.A., and Cunningham B.C. Minimization of a polypeptide hormone. Science 270 (1995) 1657-1659
14. Reineke U., Sabat R., Misselwitz R., Welfle H., Volk H.D., and Schneider-Mergener J. A synthetic mimic of a discontinuous binding site on interleukin-10. Nat. Biotechnol. 17 (1999) 271-275
15. Sun J., Li Y., Sun Y., Feng J., Yu M., and Shen B. Preparation and characterization of a monoclonal antibody against human B lymphocyte stimulator. Hridoma 25 (2006) 80-85
16. Qin W., Feng J., Zhang W., Li Y., and Shen B. A novel TNFa antagonizing peptide-Fc fusion protein designed based on CDRs of TNFa neutralizing monoclonal antibody. Biochem. Biophys. Res. Commun. 322 (2004) 1024-1028
17. Ramanujam M., Wang X., Huang W., Schiffer L., Grimaldi C., Akkerman A., Diamond B., Madaio M.P., and Davidson A. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 173 (2004) 3524-3534
18. Wang H., Marsters S.A., Baker T., Chan B., Lee W.P., Fu L., Tumas D., Yan M., Dixit V.M., Ashkenazi A., and Grewal I.S. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immun. 2 (2001) 632-637
19. Yang Z., Feng J., Hu M., Li Y., Yu M., Qin W., and Shen B. A novel hIL-6 antagonist peptide from computer-aided design contributes to suppression of apoptosis in M1 cells. Biochem. Biophys. Res. Commun. 325 (2004) 518-524